We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+13.07%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$246M
AUM Growth
-$60.8M
Cap. Flow
-$70.1M
Cap. Flow %
-28.47%
Top 10 Hldgs %
67.39%
Holding
78
New
29
Increased
8
Reduced
16
Closed
23

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$13.8M
2
MRK icon
Merck
MRK
+$12.9M
3
SBRA icon
Sabra Healthcare REIT
SBRA
+$5.57M
4
CI icon
Cigna
CI
+$4.93M
5
ELV icon
Elevance Health
ELV
+$4.91M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$15.9M
2
TAK icon
Takeda Pharmaceutical
TAK
+$14.3M
3
BAX icon
Baxter International
BAX
+$12.6M
4
LLY icon
Eli Lilly
LLY
+$12.4M
5
QGEN icon
Qiagen
QGEN
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 73.98%
2 Real Estate 2.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMEA icon
51
Biomea Fusion
BMEA
$89.9M
$286K 0.12%
+33,881
New +$289K
OYST
52
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$223K 0.09%
+19,927
New +$193K
ATNX
53
DELISTED
Athenex, Inc. Common Stock
ATNX
$133K 0.05%
45,112
+18,779
+71% +$71.2K
ABOS icon
54
Acumen Pharmaceuticals
ABOS
$167M
– –
-55,328
Closed -$555K
AVTR icon
55
Avantor
AVTR
$9.08B
– –
-75,948
Closed -$1.49M
BMY icon
56
Bristol-Myers Squibb
BMY
$131B
– –
-158,721
Closed -$11.3M
CYTK icon
57
Cytokinetics
CYTK
$10.4B
– –
-9,211
Closed -$446K
LKFT
58
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
– –
-50,822
Closed -$2.17M
HUM icon
59
Humana
HUM
$45.8B
– –
-32,729
Closed -$15.9M
LLY icon
60
Eli Lilly
LLY
$1.06T
– –
-38,311
Closed -$12.4M
MCK icon
61
McKesson
MCK
$103B
– –
-16,168
Closed -$5.5M
MMSI icon
62
Merit Medical Systems
MMSI
$5.28B
– –
-51,218
Closed -$2.89M
OHI icon
63
Omega Healthcare
OHI
$14.7B
– –
-313,762
Closed -$9.25M
ACH
64
Accendra Health
ACH
$234M
– –
-55,914
Closed -$1.35M
OPCH icon
65
Option Care Health
OPCH
$3.6B
– –
-43,457
Closed -$1.37M
PCVX icon
66
Vaxcyte
PCVX
$8.78B
– –
-52,309
Closed -$1.25M
RCUS icon
67
Arcus Biosciences
RCUS
$3.6B
– –
-97,327
Closed -$2.55M
RLMD icon
68
Relmada Therapeutics
RLMD
$553M
– –
-14,145
Closed -$524K
TAK icon
69
Takeda Pharmaceutical
TAK
$56B
– –
-1,102,280
Closed -$14.3M
TEVA icon
70
Teva Pharmaceuticals
TEVA
$41.4B
– –
-179,226
Closed -$1.45M
VCYT icon
71
Veracyte
VCYT
$3.76B
– –
-108,751
Closed -$1.8M
VTR icon
72
Ventas
VTR
$47.6B
– –
-85,683
Closed -$3.44M
MOR
73
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-68,290
Closed -$344K
MRTX
74
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-7,915
Closed -$553K
CANO
75
DELISTED
Cano Health, Inc.
CANO
– –
-2,109
Closed -$1.83M
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Endurant Capital Management held 78 positions worth $246M, down 20% from $307M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Endurant Capital Management withdrew a net $70.1M in Q4 2022, closing 23 positions and reducing 16 holdings. Its most notable exit was Humana, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Real Estate.

Against the trend, Endurant Capital Management opened a new position in Centene worth $13.8M.

  • Endurant Capital Management's largest Q4 2022 buy was Centene: 168,363 shares worth $13.8M.
  • Endurant Capital Management added most to Cigna in Q4 2022, an estimated $4.93M increase.
  • Endurant Capital Management's biggest Q4 2022 reduction was Baxter International, cutting an estimated $12.6M.
  • Endurant Capital Management fully exited Humana in Q4 2022, selling an estimated $15.9M.
  • Endurant Capital Management's ten largest holdings make up 67% of its $246M portfolio in Q4 2022.
  • Endurant Capital Management opened 29 new positions and closed 23 in Q4 2022.
  • Endurant Capital Management's portfolio value fell 20% quarter-over-quarter to $246M.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.